Skip to Main Content

Amid concerns over access to Covid-19 vaccines and treatments, Pfizer (PFE) is being urged by a prominent advocacy group to make a recently authorized pill more widely available to poor countries and avoid the inequity problems that have so far plagued the global response to the pandemic.

In a Jan. 24 letter to Pfizer chief executive officer Albert Bourla, Public Citizen argued the company is remiss for entering into supply agreements for its Paxlovid pill that “almost exclusively” cover countries based in North America and Europe while its production output is constrained. Pfizer has indicated that 120 million treatment courses will become available this year.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Create a display name to comment

This name will appear with your comment